16Oct 2024
Tofacitinib Shows Promise for Filler-Related Granulomatous Reactions

Tofacitinib Shows Promise for Filler-Related Granulomatous Reactions

A recent study indicates that Janus Kinase (JAK) inhibitors effectively treat refractory granulomatous diseases. A case involving a 50-year-old woman who developed a granulomatous reaction after a filler injection in her buttocks is reported. The patient received treatment with tofacitinib, leading to the resolution of stiffness and swelling after one year of therapy, with no reported side effects. The case suggests that tofacitinib may be viable for managing granulomatous reactions to cosmetic fillers, providing a new therapeutic avenue for similar clinical challenges.

  • #dermatology

Like

Save

Share